Channels - Vascular cognitive impairment and dementia drug‐development pipeline 2025 :: FRELIP Discovery

Similar Items: Vascular cognitive impairment and dementia drug‐development pipeline 2025

Quick Look
Advances in pharmacotherapy for vascular cognitive impairment and vascular dementia: An update of 2025
Quick Look
Use of Wearable Technology for Measuring and Characterizing Sedentary Behavior in People With Mild Cognitive Impairment and Dementia: Systematic Review
Quick Look
Alzheimer's disease drug development pipeline: 2026
Quick Look
Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
Quick Look
Druggable genome‐wide Mendelian randomization analysis identifies potential treatment targets in vascular dementia
Quick Look
Real‐time digital assessment of sleep–cognition dynamics in dementia care dyads
Quick Look
Testing Van Gool’s Hypothesis: A Method to Predict Side Effects of Cholinesterase Inhibitors in Patients with Cellular Degenerative and Vascular Dementia
Quick Look
Refining cognitive dispersion metrics for brain–behavior prediction in aging and mild cognitive impairment
Quick Look
A potential multimodal biomarker – cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment
Quick Look
Optimizing scalable approaches for early detection of cognitive impairment in primary care
Quick Look
Focal hippocampal subfield atrophy in cognitively impaired relative to cognitively unimpaired older adults is associated with memory ability
Quick Look
Development of a Japanese version of the Family Stigma Instrument for dementia
Quick Look
Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools
Quick Look
Accelerometer‐derived daily steps, cognition, and cognitive impairment in U.S. community‐dwelling older adults: The Atherosclerosis Risk in Communities Study
Quick Look
Identification of cognitive impairment using the Lancet Commission's risk factors and Medicare administrative data
Quick Look
Regional amyloid PET asymmetry and long‐term clinical trajectory in mild cognitive impairment
Quick Look
Elevated sclerostin levels in cerebrospinal fluid are associated with cognitive impairment in the Alzheimer's disease continuum
Quick Look
A combination of ketones and NAD+ precursor preserves white matter integrity in mild cognitive impairment
Quick Look
Pharmacogenetic analyses in people with dementia in Northeast Germany
Quick Look
Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease
Quick Look
Usability of the Coach-Supported Dementia Prevention App ENHANCE (Tailored Intervention for Brain Health and Cognitive Enrichment) in Older Adults: 1-Week Mixed Methods Study
Quick Look
Frontotemporal dementia in Hispanic populations: Regional and national comparisons
Quick Look
Outcome Measures for Dementia in the Advanced Stage and at the End of Life
Quick Look
Prevalence of Lewy body pathology and phenotypic associations in patients with mild cognitive impairment: Evidence from the Interceptor study